PHOENIX–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Arizona?src=hash” target=”_blank”gt;#Arizonalt;/agt;–The HonorHealth vice president of research and a retired executive at
W.L. Gore & Associates, Inc. have assumed new leadership roles with a
statewide committee charged with advancing the biosciences in Arizona.
Mark Slater has been named chair and Eve Ross the vice chair of
Arizona’s Bioscience Roadmap Steering Committee, comprised of about 100
leaders from the public and private sectors in science, health care,
business, academia, economic development, government, and policy.
Slater, the vice president for research at HonorHealth and chief
executive for the HonorHealth Research Institute, joined the committee
in 2007 and has served as vice chair since 2016. Ross, a retired
medical-technology executive and attorney at W.L. Gore & Associates,
Inc., became a committee member in 2003.
Bioscience Roadmap Steering Committee, which receives staffing
support from the Flinn
Foundation, is engaged throughout the year pursuing the goals of
Arizona’s Bioscience Roadmap, and gathers quarterly to discuss major
research, business, and policy developments that impact the biosciences
in Arizona and explore opportunities to advance the sector.
“Arizona has many bioscience success stories, and we are striving for
more through the expansion of research and commercialization, increasing
venture capital for emerging businesses, and discovering new health
treatments,” Slater said. “The committee members are actively engaged to
make these goals a reality in a sector that benefits the state’s health
Slater’s research focuses on pain perception, treatment, and
rehabilitation. He has produced more than 100 publications and received
more than $30 million in grant funding. The HonorHealth
Research Institute is focused on accelerating medical innovation in
multiple areas through clinical, translational and health care delivery
research, including an early cancer drug development program in
collaboration with the Translational Genomics Research Institute.
Slater has previously served on the medical-school faculty at the
University of California, San Diego, held leadership positions at Sharp
HealthCare and the Veterans Administration Medical Center in San Diego,
and developed medical-research data and consulting businesses.
When Ross retired in 2017, she was leading public policy and strategic
initiatives at W.L.
Gore & Associates, Inc., a global medical-device company with a
large presence in Flagstaff and north Phoenix. The first Gore
manufacturing plant in the western United States opened in Flagstaff in
the 1960s, and in 2011 a 40-acre campus in Phoenix was built to expand
the medical-products division.
Ross is a health-care attorney experienced in the commercialization of
new technologies, and a public-policy advocate for the value of medical
technology. She is a statewide civic leader and has a law degree from
Arizona State University.
“Both Mark and Eve have played critical roles in advancing the
biosciences in Arizona through their respective work, and they will
bring that same knowledge, leadership, and enthusiasm to their new roles
on the Steering Committee,” said Tammy McLeod, President and CEO of the
Slater succeeds Ron Shoopman, chair of the Arizona Board of Regents, who
joined the Steering Committee in 2005 and was named vice chair in 2007
and chair in 2016. Shoopman will remain a member of the committee.
The committee was created in the early 2000s to oversee Arizona’s
Bioscience Roadmap, the long-term strategic plan to guide the growth
and development of the state’s bioscience sector through 2025.
In April, the Flinn Foundation will host the annual Arizona’s Bioscience
Roadmap luncheons in Phoenix, Tucson, and Flagstaff to highlight the
progress of Arizona’s bioscience sector. Data on key metrics will be
updated again in 2020.